company will increase the numbers in the next earning call
buy hand over fist of you can
after conf call i feel upgrades will continue of which one may include a new major institutional player in coverage jmho
forgive this basic question, of course....... is there any reason to suspect the supply of placentas may become an issue?? I haven't seen any information on what % of placenta capacity they are, and possible supply issues? It sounds like they could sell multiples of the current run rate if there were no gating factors......
And we should finally get some 2015 numbers which will include some Medtronic numbers, 2015 over 200 million so then you can start looking for some buyout action, 7 to 10 times future revenues is what someone will pay, how far out they look will be another game to play. We also don't hear much about international Epifix sales, I know we have some international distributors.
Sorry, one more thing. I know a sports medicine doctor who is invested in mdxg who is convinced that amniofix will replace the cortisone shot, that is our wildcard. It has been mentioned many times here, nobody can predict what type of valuation mdxg would present if this scenario came to fruition. This would take many years, however speculation is what provides returns, much before the reality. Regenerative medicines are currently in vogue, mdxg is going to be in much of that spotlight. Did I mention the company is debt free and will do over 100 million at 85 percent gross profit this year, that is reality .....many are frustrated at this wall at 7, for those of us in this for 4 or more years you only have to look back to 2 years ago when we were stuck at 1.25, hanging at 7 bucks 2 years later isn't so bad, be patient even though everyone wants immediate returns, we are going much much higher. Study the chart of Jazz over the past 5 years to see what could and I believe will happen to mdxg over time.